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Abstract In an effort to identify genes related to the cell line
chemosensitivity and to evaluate the functional relationships
between genes and anticancer drugs acting by the same
mechanism, a supervised machine learning approach called
support vector machine was used to label genes into any of the
five predefined anticancer drug mechanistic categories. Among
dozens of unequivocally categorized genes, many were known to
be causally related to the drug mechanisms. For example, a few
genes were found to be involved in the biological process
triggered by the drugs (e.g. DNA polymerase epsilon was the
direct target for the drugs from DNA antimetabolites category).
DNA repair-related genes were found to be enriched for about
eight-fold in the resulting gene set relative to the entire gene set.
Some uncharacterized transcripts might be of interest in future
studies. This method of correlating the drugs and genes provides
a strategy for finding novel biologically significant relationships
for molecular pharmacology. & 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
The identi¢cation of drug^gene functional relationships is
always an important issue in molecular pharmacology. Locat-
ing a drug target is the ¢rst step in rational drug design.
Knowledge of the underlying genetic pathways a¡ected by a
drug enables better understanding of the drug’s mechanism
and the identi¢cation of gene markers for chemotherapy
might be useful in clinical diagnosis. Recently, cDNA micro-
arrays were used to assess gene expression pro¢les of 60 hu-
man cancer cell lines [1]. This gene expression database, to-
gether with the independently developed drug activity
database recording anticancer pro¢les of various compounds
against the same 60 cancer cell lines [2], provided the oppor-
tunity to take a global, systematic look at tumor molecular
biology and pharmacology. The gene expression pattern or
the drug activity pattern can be viewed as ¢ngerprints for a
gene or a drug that re£ects their intrinsic properties. For
example, drug activity pattern is known to be closely related
to the drug’s anticancer mechanism [3], and gene expression
pattern is found to be closely related to the gene’s biological
function [4]. Whether a cell line is sensitive or resistant to a
certain set of drugs is determined by what kind of genes it
expresses and by how much these genes express. Therefore,
the underlying causal drug^gene relationships might be visu-
alized as the similarity between the two pro¢les. Based on this
biological principle, Scherf et al. ¢rst raised the idea of asso-
ciating drugs with genes using these two pro¢les [5]. An earlier
work of Weinstein et al. denoted that drugs with similar anti-
cancer mechanisms (within the same mechanistic category)
have similar drug activity patterns, while drugs with di¡erent
anticancer mechanisms (di¡erent mechanistic categories) have
di¡erent drug activity patterns [3]. Therefore, each drug mech-
anistic category describes a unique probability distribution for
the drug activity pro¢le vectors. Mathematically, if we ab-
stract both the gene expression pro¢le and the drug activity
pro¢le as random vectors, we may treat them undiscriminat-
ingly and give them a uni¢ed term as ‘abstract pro¢le vector’.
The main assumption we hold is that, when the abstract pro-
¢le vector of a gene is predicted with a high probability to be
a sample drawn from one of the unique probability distribu-
tions (here, each probability distribution is equated with a
certain mechanistic category), the gene and the drugs from
that mechanistic category are probably biologically related.
Based on this assumption, a newly developed machine learn-
ing method called support vector machine (SVM) [6] was used
here to locate such drug^gene relationships. The drug activity
pro¢les were used as training set to train the SVM and the
gene expression pro¢les were used as test set to predict the
mechanistic category they fell into. This paper analyzes
whether drug activity patterns and gene expression patterns
were able to identify genes related to the drug anticancer
mechanism. Also, we aimed at providing for further experi-
ments the uncharacterized gene candidates that might poten-
tially be related to cancer chemotherapy e⁄cacies.
2. Materials and methods
2.1. Materials
Gene expression was measured in 60 cell lines by microarrays and
recorded as the base 2 logarithm of the ratios of the relative mRNA
level of each cell line to a common reference sample pool [1]. Drug
activity was expressed as the negative logarithm of GI50, where GI50
was the concentration of the compound needed to cause 50% cell
growth inhibition [7]. Weinstein et al. labeled 131 well-studied drugs
into each of the six mechanistic categories: alkylating agents (Ak),
topoisomerase I inhibitors (T1), topoisomerase II inhibitors (T2),
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RNA/DNA antimetabolites (Ri), DNA antimetabolites (Di) and anti-
mitotic agents (Mi) [3]. The cell line set used for assessing the gene
expression pro¢les and the cell line set used for assessing the drug
activity pro¢les of the 131 drugs have 50 common members. Only
data for these 50 cell lines was used for further calculation. 1400
compounds that have been well validated were selected according to
Scherf et al. from a public database (http://discover.nci.nih.gov) [5].
The 1400-compound set was then combined with the 131-drug set and
the union was further winnowed to eliminate those with more than
¢ve missing values. 1217 drugs passed this ¢lter. 6357 genes with less
than four missing values and with standard deviations larger than 0.5
were selected from the original database. The Unigene cluster identi-
¢er for each gene entry was extracted from the newest release of the
SOURCE database (http://genome-www.stanford.edu/source). After
removing chimera clones, repetitive clones and clones not included
by the Unigene database, 4864 genes were reserved. Altogether, this
work used a 1217U50 drug matrix and a 4864U50 gene matrix.
Normalization was done so that every row of the two matrices has
a 0 mean and a standard deviation of 1. The lists of ¢nal cell lines and
drugs in mechanistic categories are available in Tables A1 and A2 of
the Appendix.
2.2. Methods
For each mechanistic category, a corresponding binary SVM clas-
si¢er was constructed. These classi¢ers were one-versus-rest classi¢ers
(‘one’: positive class, ‘rest’ : negative class). For each SVM classi¢er,
compounds from each mechanistic category were used as the positive
training set, while all the other compounds were used as the negative
training set. Since the T1 category was comprised solely of campto-
thecin derivatives, this category was not used as a positive set. There-
fore, altogether ¢ve binary SVM classi¢ers were built and trained (see
Fig. 1 in Appendix).
A SVM requires the speci¢cation of two parameters: the kernel
function and the penalty magnitude for violating the soft margin.
The penalty magnitude was determined in the light of a trade-o¡
between the sensitivity and the speci¢city. In this work, the drug
mechanistic categories contained very few members relative to the
total number of drugs in the data set. Therefore, there was an extreme
imbalance between the number of positive and negative training ex-
amples. Without any modi¢cation, the SVM will misclassify all mem-
bers of the training set as negative examples in the presence of noise.
The problem was combated by modifying the diagonal of the kernel
matrix during the training step according to Brown et al. [4]. For each
positive example, a constant V (nþ/N) was added to the diagonal
entity while for each negative example, a constant V (n3/N) was added
where N is the total number of training examples, nþ, n3 are the
number of positive and negative training examples. The scale factor
V was set to 0.1. This method assigns a larger penalty to false neg-
atives than to false positives. Polynomial kernel functions with powers
of 1, 2, 3 and radial basis kernel were tested. For each drug mecha-
nistic category, the training set was randomly split into 10 parts and a
10-fold cross-validation was carried out. To eliminate the e¡ects in-
troduced by a certain splitting, such splitting/validation procedures
were repeated six times and the average cost for the six independent
splittings was used to assess the optimal classi¢cation. The cost func-
tion to be optimized was de¢ned as fp+2fn where fp is the number of
false positives and fn is the number of false negatives. Again, the false
negatives were weighted more heavily because of the imbalance in
thenumber of positive and negative training examples. After building
the optimized SVM, a 4864-gene set was used as test set to predict
their class labels.
To compare the frequency of certain function keywords in the pre-
dicted gene set and in the entire gene set, annotation record for each
gene was also retrieved from the SOURCE database. Detail descrip-
tions for the ¢elds in each record can be found at http://genome-
www5.stanford.edu/MicroArray/help/SOURCE/resultsBatchHelp.html.
Altogether, four ¢elds contained function annotation information.
They are the ¢elds of ‘Summary Function’, ‘Gene Ontology Annota-
tions’, ‘Other Ontology Annotations’ and ‘Enzyme Function’. We
searched all these four ¢elds for certain keywords and compared their
frequency in the two gene sets. For the predicted gene set, each gene
bearing the keywords was also arti¢cially looked through to make
sure that they are indeed involved in the expecting biological process
to eliminate false positives. The keywords used for assessing genes
involved in DNA repair were ‘DNA’ and ‘REPAIR’; the keywords
used for assessing genes involved in apoptosis and oncogenesis were
‘APOPTOSIS’ or ‘APOPTOTIC’ or ‘ONCOGENE’ or ‘ONCOGEN-
ESIS’; the keywords used for assessing genes involved in protein syn-
thesis were ‘PROTEIN SYNTHESIS’ or ‘TRANSLATION’ or ‘RI-
BOSOMAL PROTEIN’. To eliminate the possibility that the
enrichment for certain function keywords was simply due to more
annotated genes in the predicted gene set than in the entire set, fre-
quency normalized by the number of annotated genes was also calcu-
lated.
3. Results
3.1. Selection of the kernel function and the SVM accuracy
After ¢ltering, the Ak, T2, Ri, Di and Mi categories (each
positive training set) contained 34, 16, 17, 16 and 13 members.
Each binary SVM classi¢er was constructed so as to represent
the unique probability distribution for the corresponding
mechanistic category. These classi¢ers were then used to pre-
dict which mechanistic category each gene would fall into
according to its similarity to any of the ¢ve categories. If a
gene did not fall into any of the ¢ve categories (all the dis-
criminant values were less than zero), the gene was assigned to
the ‘unknown’ category and the gene was not kept for further
analysis. Given the data set, a proper kernel function and its
parameters must be chosen to construct the SVM classi¢er.
This selection is important because the type of kernel function
determines the sample distribution in the mapping space. A
¢rst degree kernel is equal to a linear classi¢er. A second
degree kernel re£ects two-fold interactions between the mea-
sured data and so on for degree 3. There are no successful
theoretical methods for determining the optimal kernel func-
tion and its parameters. After some preliminary computa-
tions, we found that as a whole the second degree polynomial
kernel performed better than the ¢rst or third degree kernels
or the radial kernel and is more appropriate in this context.
Therefore, the second degree polynomial kernel was used to
Table 1
Average cost of six independent 10-fold cross-validation
Mechanistic categories Di¡erent kernel functions
Polynomial 1 Polynomial 2 Polynomial 3 Radial basis
Ak 12.3 9.8 20.5 7.5
T2 9.8 6.2 13.5 6.7
Ri 20.7 13.7 17.5 14.3
Di 22.3 8.3 15.5 14.3
Mi 15.0 7.0 7.2 10.5
Total cost 80.1 45.0 74.2 53.3
The cost function is the number of false positive plus the double number of false negative.
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Table 2
List of genes with positive labels
Bold genes were the examples discussed in the text. For genes included by the GeneCard database, their GeneCard identi¢ers are given. For
ESTs, the clone IDs were given.
FEBS 26171 7-6-02
L. Bao, Z. Sun/FEBS Letters 521 (2002) 109^114 111
build the binary SVMs. The cross validation results are listed
in Table 1.
3.2. Genes interpreting the common anticancer mechanism are
enriched in the predicted gene set
All the genes having positive labels (namely, they do not
belong to the ‘unknown’ category) are listed in Table 2. 19,
13, 18, 22 and 3 genes were assigned to the Ak, T2, Ri, Di and
Mi categories respectively. Table 3 compares the frequency of
some gene function de¢nitions between the predicted gene set
and the entire gene set (see the Appendix for more details). It
is known that compounds from the Ak, T2, Ri and Di cate-
gories are able to induce DNA damage and genes involved in
the DNA repair process are believed to a¡ect the compound
e⁄cacies. Therefore, if our method was e¡ective, DNA repair
related genes were expected to be enriched in the predicted set
than in the entire set. Table 3 shows that it is indeed the case.
The DNA repair-related genes were enriched for about eight-
fold in the predicted gene set, demonstrating the e¡ectiveness
of our approach to catch causal drug^gene relations. Another
comparison was done for the genes involved in the apoptosis
and oncogenesis process. The richness is not as signi¢cant as
the DNA repair related genes, but we can still see a two-fold
enrichment.
3.3. Individual causally related drug^gene examples
Several genes were closely related to the idiosyncracies of
each mechanistic category. For example, the Ak category con-
tains an apoptosis adaptor protein FADD. Overexpression of
FADD sensitizes tumor cells to cisplatin (NSC 119875, and
Ak agent) triggered cell death and cisplatin induced the re-
cruitment of FADD to the apoptotic complex [8]. The Ri
category included several genes involved in translation pro-
cesses (Table 3). It is well known that the proportion between
ribosomal proteins and rRNAs is precisely regulated; there-
fore, inhibiting RNA synthesis might also a¡ect the ribosomal
proteins as well as the protein synthesis process. As an exam-
ple, a Ri agent 5-£uorouracil (NSC 19893) was known to
inhibit the pre-rRNA processing and a¡ect translation process
[9]. Another example of the Ri category is the gene MTHFD2.
MTHFD2 encodes a mitochondrial enzyme for tetrafolate
metabolism and is involved in initiation of mitochondrial pro-
tein synthesis, a process a¡ected by the antifolates from this
category [10]. Very interestingly, the gene’s cytosol counter-
part MTHFD1 is known to be inhibited by the antifolates
from this category [11]. An interesting gene from Di category
is POLE, the DNA polymerase epsilon, which can be directly
inhibited by some compounds from this category like ara-C
(NSC 63878) [12]. Hence, POLE is an example of direct drug
target found in this work. In the T2 category, the gene CBFB
encodes a core-binding factor that plays multiple roles in the
biological process such as apoptotic response and hematopoi-
esis. CBFB was known to be involved in chromosome inver-
sion events and to form a fusion protein with gene MYH11
preferentially in topoisomerase inhibitor-treated patients [13].
In the Mi category, PFN1 encodes an actin binding protein
which plays a role in the cell shaping [14]. It might be related
to mitosis. Therefore, the correlation between PFN1 and the
Mi was hypothesized.
4. Discussion
SVM has been successfully applied to categorize yeast gene
according to their functions using gene expression pro¢les [4].
Here we extended that idea to identifying drug^gene relation-
ships. The gene expression pro¢le or the drug activity pro¢le
can be viewed as ¢ngerprints for a gene or a drug. Weinstein
et al. indicated that drug activity pro¢les were rich in infor-
mation about mechanisms and each mechanistic category
could be discriminated from the others [3]. The SVM cross
validation results support this idea. For four out of ¢ve cat-
egories, the de¢ned costs for the optimized classi¢ers were less
than 10. SVM has several advantages over such machine
learning problems. First, SVM avoids over¢tting and ¢nding
trivial results (a common problem in machine learning ¢eld)
by implementing the structural risk minimization principle.
Second, SVM condenses the information of the training sam-
ples into a small number of samples called support vectors. If
all the other training samples are removed and SVM is re-
trained, the solution would keep unchanged. This allows SVM
to classify new examples e⁄ciently, since the majority of the
training examples can be safely ignored. Third, the solution of
SVM was not a¡ected by the initial conditions. Therefore, it is
quite easy to be realized.
In this paper, we have demonstrated that SVM can be used
to determine drug^gene functional relationships with both rel-
atively high sensitivity and high speci¢city. Since the gene
expression pro¢les are those for untreated cells, the relation-
ships established between drugs and genes should ¢rst be con-
sidered correlative and not de¢nitely causal. However, the
literature indicated that the drug^gene groups found here
were rich in causal relationships. It is not surprising, both
biologically and algorithmically. Biologically, without regard
to experiment errors, it seems intuitively reasonable to pre-
sume that a gene is probably related to a drug mechanistic
category if the gene’s expression pattern is similar to the drug
activity patterns for that category. The intrinsic factors for the
cell lines behavior to compounds acting by the same mecha-
Table 3
Di¡erent gene function distributions between the predicted set and the entire set
Function Representative gene lists Frequency in the
predicted set (%)
Frequency in the
entire set (%)
Enriched
multiple
DNA Repair LIG3 (Ak), RECQL (Ak), RPA2 (Di), POLE (Di), MLH1 (Di) 6.94 (12.20) 0.84 (1.62) 8.3 (7.5)
Apoptosis and
oncogenesis
FADD (Ak), RAB5C (Ak), PDCD8 (T2), CBFB (T2), MLH1 (Di),
RALGDS (Di), TGFB1 (Ri), PDCD4 (Mi)
10.67 (18.60) 4.85 (9.35) 2.2 (2.0)
Translation EEF1B2 (Ri), RPL21 (Ri), RPL27 (Ri), AARS (Ri) 22.22 (36.36) 2.14 (4.12) 10.4 (8.8)
In column 2, predicted category is shown in the parentheses. In columns 3^5, numbers before the parentheses represent the frequency or multi-
ple with respect to all the transcripts including ESTs, and numbers within the parentheses represent the frequency or multiple with respect to
only the annotated genes (a subset of the former).
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nism are the genes involved in the biological process under-
lying the drugs’ anticancer e⁄cacies. Furthermore, anecdotal
evidence exists that causally related drug^gene pairs exhibit
similar pro¢les [5]. Algorithmically, in many cases SVM out-
performs other machine learning methods like neural net-
works. Scherf et al. ¢rst used average-linkage clustering to
associate genes and drugs, but they had di⁄culty locating
true functional correlations from the noise [5]. Butte et al.
used the permutation method to deduce a very stringent cor-
relation coe⁄cient threshold [15]. Although they did ¢nd one
hypothetical gene^drug pair that passed the threshold, the
sensitivity seemed too low (one hypothetical functional pair
out of 33 million drug^gene pairs). The similarity measure
here was more than just linear correlations. Most importantly,
as opposed to these two approaches that associate a single
gene with a single drug during the ¢rst step, our approach
associated a group of genes with a group of drugs acting by
the same mechanism. Bringing genes into the context of drug
mechanism will give more information on the gene functions
than simply correlating drugs and genes. For unknown ESTs,
this approach provides useful clues for their roles in cancer
occurrence and chemotherapy; therefore, in some sense, this
approach may also be used in a limited way to predict gene
functions. Certain ESTs are indicated as deserving high prior-
ity in future molecular studies. Together with other informa-
tion like sequence features, subcellular locations and so on,
the functions of these ESTs might be disclosed.
There are also several limitations for this method. First,
since only the gene expression pro¢les were taken into ac-
count, our method can work only when the drug^gene func-
tional relationships were embodied at the transcriptional level.
Given the fact that drug^gene functional relationships may
take place at various levels, this method can only identify a
subset of all the potential causally relationships. Second, this
approach is a supervised learning method. The major limita-
tion is that a priori knowledge of drug mechanisms is re-
quired. These ¢ve categories were well studied mechanistic
categories. Although they account for only a small proportion
of the anticancer compound database, yet with more and
more mechanistic categories identi¢ed, this approach would
exert better use.
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Appendix
Table A1
50 cancer cell lines used in this work
Tissue Cell lines
CNS SNB-19, SNB-75 SF-268, SF-295, SF-539, U251
CO COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12,
SW-620
LC A549/ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-
H23, NCI-H322M, NCI-H460, NCI-H522
LE CCRF-CEM, HL-60, K-562, MOLT-4, RPMI-8226, SR
ME LOXIMVI, M14, MALME-3M, SK-MEL-2, SK-MEL-5,
SK-MEL-28, UACC-62, UACC-257
OV IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8,
SK-OV-3
RE 786-0, A498, ACHN, CAKI-1 RXF-393, SN12C, TK-10,
UO-31
The tissue origin of 50 cell lines was expressed here in abbrevia-
tions. CNS: Central nervous system; CO: colon; LC: lung; LE:
leukemia; ME: melanoma; OV: ovarian; RE: renal.
Fig. 1. Illustration of the method. A^E: Denotes the ¢ve drug mechanistic categories: Ak, T2, Ri, Di, Mi. In the training phase, inputs (solid
arrows) are the drug activity pro¢les (drug matrix). Take A/VA classi¢er as an example, drugs within category A serve as positive training
samples, while all the other drugs serve as negative training samples (VA category indicates they do not belong to the category A). Altogether
¢ve parallel SVM classi¢ers were trained (A^E). In the predicting phase, inputs (dashed arrows) are the gene expression pro¢les (gene matrix).
For each input gene, each of the ¢ve trained SVM classi¢ers will give a scalar output ^ the discriminant value. If the maximum of the ¢ve out-
puts is larger than 0, the gene is assigned to the corresponding drug mechanistic category; otherwise if all the ¢ve outputs are smaller than 0,
the gene is assigned to the ‘unknown’ category (a sixth category which is uninteresting). Most genes were found to fall into the ‘unknown’ cate-
gory.
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Table A2
Five mechanistic categories serving as ¢ve positive training sets
Mechanistic
categories
Anticancer drug NSC number
Ak (34) 750, 762, 3088, 6396, 8806, 9706, 25154, 26980, 34462, 56410, 73754, 79037, 95441, 95466, 102627, 119875, 132313, 135758,
142982, 167780, 172112, 182986, 241240, 256927, 271674, 296934, 329680, 338947, 344007, 348948, 353451, 357704, 363812,
409962
T2 (16) 82151, 122819, 123127, 141540, 164011, 249992, 267469, 268242, 269148, 301739, 308847, 337766, 349174, 354646, 355644,
366140
Ri (17) 740, 19893, 102816, 126771, 132483, 139105, 143095, 148958, 153353, 163501, 174121, 184692, 224131, 264880, 352122, 368390,
633713
Di (16) 752, 755, 1895, 27640, 32065, 51143, 63878, 71261, 71851, 95678, 107392, 118994, 127716, 145668, 303812, 330500
Mi (13) 757, 33410, 49842, 67574, 83265, 125973, 153858, 332598, 361792, 376128, 406042, 608832, 609395
Table A3
Frequency of the gene function keywords in the predicted set and entire set
Function Related categories Predicted gene set Entire gene set
positivea knownb allc positivea knownb allc
DNA repair Ak, T2, Ri, Di 5 41 72 41 2524 4864
Apoptosis/oncogenesis Ak, T2, Ri, Di, Mi 8 43 75 236 2524 4864
Protein synthesis Ri 4 11 18 104 2524 4864
aNumber of genes with function speci¢ed in the ¢rst column.
bNumber of genes having function annotations.
cTotal number of the genes including ESTs.
References
[1] Ross, D.T., Scherf, U., Eisen, M.B., Perou, C.M., Rees, C.,
Spellman, P., Iyer, V., Je¡rey, S.S., VandeRijn, M., Waltham,
M., Pergamenschikov, A., Lee, J.C., Lashkari, D., Shalon, D.,
Myers, T.G., Weinstein, J.N., Botstein, D. and Brown, P.O.
(2000) Nat. Genet. 24, 227^235.
[2] Weinstein, J.N., Myers, T.G., O’Connor, P.M., Friend, S.H.,
Fornace Jr., A.J., Kohn,, K.W., Fojo, T., Bates, S.E., Rubin-
stein, L.V., Anderson, N.L., Buolamwini, J.K., van Osdol,
W.W., Monks, A.P., Scudiero, D.A., Sausville, E.A., Zaharevitz,
D.W., Bunow, B., Viswanadhan, V.N., Johnson, G.S., Wittes,
R.E. and Paull, K.D. (1997) Science 275, 343^349.
[3] Weinstein, J.N., Kohn, K.W., Grever, M.R., Viswanadhan, V.N.,
Rubinstein, L.V., Monks, A.P., Scudiero, D.A., Welch, L., Kout-
soukos, A.D., Chiausa, A.J. and Paull, K.D. (1992) Science 258,
447^451.
[4] Brown, M.P., Grundy, W.N., Lin, D., Cristianini, N., Sugnet,
C.W., Furey, T.S., Ares Jr., M. and Haussler, D. (2000) Proc.
Natl. Acad. Sci. USA 97, 262^267.
[5] Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K.,
Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., An-
drews, D.T., Scudiero, D.A., Eisen, M.B., Sausville, E.A., Pom-
mier, Y., Botstein, D., Brown, P.O. and Weinstein, J.N. (2000)
Nat. Genet. 24, 236^244.
[6] Cortes, C. and Vapnik, V. (1995) Mach. Learn. 20, 273^293.
[7] Boyd, M.R. and Paull, K.D. (1995) Drug Dev. Res. 34, 91^
109.
[8] Micheau, O., Solary, E., Hammann, A. and Dimanche-Boitrel,
M.T. (1999) J. Biol. Chem. 274, 7987^7992.
[9] Ghoshal, K. and Jacob, S.T. (1997) Biochem. Pharmacol. 53,
1569^1575.
[10] Wallace, R.B. and Freeman, K.B. (1974) Biochim. Biophys. Acta
366, 466^473.
[11] Hollinger, J.L., Hommes, O.R., van de Wiel, T.J., Kok, J.C. and
Jansen, M.J. (1982) J. Neurochem. 38, 638^642.
[12] Mirzayans, R., Dietrich, K. and Paterson, M.C. (1993) Carcino-
genesis 14, 2621^2626.
[13] Dissing, M., Le Beau, M.M. and Pedersen-Bjergaard, J. (1998)
J. Clin. Oncol. 16, 1890^1896.
[14] Witke, W., Sutherland, J.D., Sharpe, A., Arai, M. and Kwiat-
kowski, D.J. (2001) Proc. Natl. Acad. Sci. USA 98, 3832^3836.
[15] Butte, A.J., Tamayo, P., Slonim, D., Golub, T.R. and Kohane,
I.S. (2000) Proc. Natl. Acad. Sci. USA 97, 12182^12186.
FEBS 26171 7-6-02
L. Bao, Z. Sun/FEBS Letters 521 (2002) 109^114114
